Adeno-Associated Virus (AVV) Vectors In Gene Therapy Global Market Report 2026

Description

Adeno-associated virus (AAV) vectors in gene therapy are sophisticated delivery systems that carry genetic material into cells to address a variety of genetic disorders. Their main objective is to achieve targeted, long-term therapeutic effects by repairing or altering defective genes. AAV vectors are prized for their safety, minimal immunogenicity, and capability to deliver genes to both dividing and non-dividing cells, facilitating the creation of precise and lasting gene therapies that promote personalized medicine and revolutionize the treatment of rare and inherited diseases.

The primary types of adeno-associated virus (AAV) vectors include gene augmentation, immunotherapy, and other therapeutic approaches. Gene augmentation involves the therapeutic delivery of a functional gene into a cell to replace or compensate for a defective or missing gene. This can be carried out using various gene delivery techniques, such as ex vivo and in vivo methods. It is implemented across different operational scales, including preclinical, clinical, and commercial stages. The targeted therapeutic areas encompass genetic disorders, hematological disorders, infectious diseases, metabolic disorders, ophthalmic disorders, muscle disorders, and neurological conditions.

Tariffs have affected the adeno-associated virus vectors in gene therapy market by increasing the cost of imported plasmids, cell culture materials, and viral manufacturing reagents. These impacts have been most pronounced in clinical and commercial-scale production, particularly in north america and europe where advanced inputs are globally sourced. Asia-pacific manufacturers have experienced supply chain delays. However, tariffs have accelerated domestic vector manufacturing and local bioprocess infrastructure development.

The adeno-associated virus (avv) vectors in gene therapy market research report is one of a series of new reports from The Business Research Company that provides adeno-associated virus (avv) vectors in gene therapy market statistics, including adeno-associated virus (avv) vectors in gene therapy industry global market size, regional shares, competitors with a adeno-associated virus (avv) vectors in gene therapy market share, detailed adeno-associated virus (avv) vectors in gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the adeno-associated virus (avv) vectors in gene therapy industry. This adeno-associated virus (avv) vectors in gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adeno-associated virus (avv) vectors in gene therapy market size has grown rapidly in recent years. It will grow from $3.16 billion in 2025 to $3.7 billion in 2026 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to advancements in viral vector safety, rare genetic disorder research, clinical gene therapy success, regulatory approvals, academic research investments.

The adeno-associated virus (avv) vectors in gene therapy market size is expected to see rapid growth in the next few years. It will grow to $6.99 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. The growth in the forecast period can be attributed to commercial gene therapy launches, scalable vector production demand, precision medicine expansion, orphan drug incentives, global clinical trial growth. Major trends in the forecast period include expansion of gene augmentation therapies, rising demand for rare disease gene treatments, growth of in vivo gene delivery, increased commercial-scale vector manufacturing, focus on long-term therapeutic durability.

The growing emphasis on gene-based therapies is expected to drive the expansion of adeno-associated virus (AAV) vectors in the gene therapy market in the coming years. Gene-based therapies are treatments that alter or manipulate genes to prevent, treat, or cure diseases at the molecular level. Progress in genetic research is fueling the increasing focus on developing gene-based therapies, as it improves the accuracy and effectiveness of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy support the development of gene-based therapies by delivering therapeutic genes safely and efficiently into target cells, due to their low immunogenicity and capacity for long-term gene expression. For example, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies reached $5.9 billion, marking a 38% increase from 2022. Consequently, the growing emphasis on developing gene-based therapies is driving the growth of the adeno-associated virus (AAV) vectors market.

Major companies operating in the adeno-associated virus (AAV) vectors in the gene therapy market are emphasizing advanced innovation, such as customized vector diversity for assay adaptability to enhance target tissue precision, increase therapeutic effectiveness, and accelerate the creation of personalized gene therapies across multiple indications. Customized vector diversity for assay adaptability refers to employing various AAV serotypes or constructs to support different analytical tests and therapeutic applications. For example, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials aim to meet the expanding requirements of cell and gene therapy (CGT) development. The portfolio enables a smoother transition from early-stage research to GMP-grade production and helps standardize processes while improving consistency in viral vector manufacturing. This launch addresses a significant challenge in scaling CGT programs toward clinical and commercial readiness.

In March 2023, Ginkgo Bioworks, a US-based biotechnology company, acquired StrideBio's AAV capsid discovery and engineering platform assets for an undisclosed sum. Through this acquisition, Ginkgo Bioworks seeks to strengthen its end-to-end research and development capabilities in gene therapy, with a particular focus on developing novel adeno-associated virus (AAV) capsids for enhanced gene delivery. StrideBio is a US-based biotech company specializing in engineered AAV capsids for gene therapy applications.

Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adeno-associated virus (avv) vectors in gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adeno-associated virus (AAV) vectors in gene therapy market consists of revenues earned by entities by providing services such as gene delivery solutions, targeted therapeutic development, long-term gene expression, and treatment of genetic disorders through safe and efficient viral vector technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The adeno-associated virus (AAV) vectors in gene therapy market includes sales of viral vector delivery systems used for transporting genetic material into patient cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses adeno-associated virus (avv) vectors in gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adeno-associated virus (avv) vectors in gene therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adeno-associated virus (avv) vectors in gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type of Therapy: Gene Augmentation; Immunotherapy; Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo; In Vivo
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By Target Therapeutic Area: Genetic Disorders; Hematological Disorders; Infectious Diseases; Metabolic Disorders; Ophthalmic Disorders; Muscle Disorders; Neurological Disorders; Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders; Neurological Disorders; Muscular Disorders; Ophthalmological Disorders; Metabolic Disorders
2) By Immunotherapy: Oncology; Infectious Diseases; Autoimmune Disorders; Vaccine Development; T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support; RNA Interference; Neuroprotection and Neuroregeneration; Anti-Inflammatory Applications; Regenerative Medicine
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Novartis AG; Astellas Gene Therapies Inc.; Biogen Inc.; Sarepta Therapeutics Inc.; Oxford BioMedica plc; Rocket Pharmaceuticals Inc.; Aldevron LLC; REGENXBIO Inc.; uniQure N.V.; Passage Bio Inc.; Voyager Therapeutics Inc.; Dyno Therapeutics Inc.; MeiraGTx Holdings plc; Abeona Therapeutics Inc.; 4D Molecular Therapeutics Inc.; GenSight Biologics S.A.; Taysha Gene Therapies Inc.; LogicBio Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH4MAAVA01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Industry 4.0 & Intelligent Manufacturing
- 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Expansion Of Gene Augmentation Therapies
- 4.2.2 Rising Demand For Rare Disease Gene Treatments
- 4.2.3 Growth Of In Vivo Gene Delivery
- 4.2.4 Increased Commercial-Scale Vector Manufacturing
- 4.2.5 Focus On Long-Term Therapeutic Durability

5. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Analysis Of End Use Industries

5.1 Biopharmaceutical Companies
5.2 Contract Development And Manufacturing Organizations
5.3 Research Institutions
5.4 Gene Therapy Centers
5.5 Clinical Trial Facilities

6. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Size, Comparisons And Growth Rate Analysis
7.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segmentation

9.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gene Augmentation, Immunotherapy, Other Type of Therapy
9.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Gene Delivery Method Used, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Ex Vivo, In Vivo
9.3. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Preclinical, Clinical, Commercial
9.4. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Target Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
9.5. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Gene Augmentation, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
9.6. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
9.7. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Sub-Segmentation Of Other Type of Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine

10. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regional And Country Analysis

10.1. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

11.1. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

12.1. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

13.1. India Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

14.1. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

15.1. Australia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

16.1. Indonesia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

17.1. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

18.1. Taiwan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

19.1. South East Asia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

20.1. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

21.1. UK Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

22.1. Germany Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

23.1. France Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

24.1. Italy Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

25.1. Spain Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

26.1. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

27.1. Russia Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

28.1. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

29.1. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

30.1. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

31.1. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

32.1. Brazil Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

33.1. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

34.1. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market, Segmentation By Type of Therapy, Segmentation By Type of Gene Delivery Method Used, Segmentation By Scale of Operation, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regulatory and Investment Landscape

36. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Company Profiles

36.1. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Company Profiles
- 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Astellas Gene Therapies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Other Major And Innovative Companies

Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.

38. Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market

40. Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market High Potential Countries, Segments and Strategies

40.1 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2030 - Countries Offering Most New Opportunities
40.2 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2030 - Segments Offering Most New Opportunities
40.3 Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer